Cholangiocarcinoma News and Research

RSS

Rising liver cancer rates highlight need for urgent action worldwide

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer.

29 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025

Innovative approach for the development of next-generation cancer therapies targeting FGFR2/3

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers.

4 Jul 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025

‘Cell line atlas’ can help better understand biliary tract cancer biology

Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a rare and aggressive group of cancers, carrying one of the worst prognoses in all of oncology.

12 May 2025

RANBP2 identified as key regulator in the progression of multiple solid tumors

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

12 May 2025

Firefighting chemicals leave brain cancer-linked mutations, study shows

Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting occupational risk. The study highlights a clear link between firefighting, chemical exposure, and brain cancer mutations.

13 Mar 2025

Exploring the molecular characteristics of hepatic biliary adenofibroma

Hepatic biliary adenofibroma (BAF) is a rare benign bile duct neoplasm that has garnered increasing attention due to its potential role as a precursor lesion for intrahepatic cholangiocarcinoma (iCCA).

28 Feb 2025

New insights into rare liver cancer as clinical trial for treatment begins

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.

17 Jan 2025

New clinical trial aims to extend survival for bile duct cancer patients

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumor.

17 Jan 2025

Prenatal cfDNA testing uncovers hidden cancers in pregnant individuals

Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to screen for chromosomal disorders in the fetus.

4 Dec 2024

Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment

Researchers investigate the spatial organization of cancer cells and the tumor microenvironment.

31 Oct 2024

Age-related fibroblast changes in males drive aggressive melanoma

Age-related changes in the fibroblasts, cells that create the skin's structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to research in mice by the Johns Hopkins Kimmel Cancer Center.

6 Sep 2024

Researchers demonstrate a new method to combat pancreatic cancer

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method to combat pancreatic cancer.

28 Aug 2024

Innovative dual-drug strategy for colorectal cancer treatment

A combination of two drugs was capable of suppressing tumors in a non-conventional manner. Instead of inhibiting tumor cell division, as the most widely used medications do, the strategy consisted of hyperactivating oncogenic signaling by these cells to the point where they became stressed.

27 Jul 2024

Scientists identify over 5,000 genetic variants that enable certain cancers to thrive

Researchers performed saturation genome editing of the BAP1, whose dysfunction is related to cancer and impaired neurodevelopment.

10 Jul 2024

Challenges in treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma (CCA).

20 Jun 2024

Innovative FAP-targeted radioligand therapy controls disease progression in sarcoma

Fibroblast activation protein (FAP)-targeted radioligand therapy is safe and effective for treating patients with progressive metastatic tumors, specifically advanced sarcomas, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

10 Jun 2024

Phase 1 trial for EBC-129 progresses into dose expansion

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

24 May 2024

Study proposes a novel therapeutic avenue for tackling EHF-induced cholangiocarcinogenesis

This study is led by Dr. Yiming Luo (Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) and Professor. Huifang Liang (Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology).

14 May 2024